来自Euphorbia fischeriana的迪特尔类,具有Kv1.3抑制活性
Qin Cai1, Hong-Jing Zha1, Shi-Ying Yuan2
1Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, People's Republic of China.
这项研究分离了新型Euphorbia diterpenoids,发现宏环亚亚和拉提兰有效地阻断Kv1.3通道. 化合物8显示出有希望的选择性,表明自身免疫性疾病治疗的潜力.
科学领域:
- 自然产品化学 自然产品化学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 欧比亚二特类是已知的Kv1.3离子通道抑制剂.
- 之前的研究主要集中在亚特罗和亚特罗骨上.
- 对来自Euphorbia物种的其他二形骨进行了有限的调查.
研究的目的:
- 从Euphorbia fischeriana中分离和表征新型的双虫.
- 评估隔离的迪特尔类的Kv1.3抑制活性.
- 探索这些化合物对自身免疫性疾病的治疗潜力.
主要方法:
- 从Euphorbia fischeriana的上空部分中提取甲醇.
- 使用光谱数据和X射线衍射,分离和结构阐明diterpenoids.
- 在体外测试以评估Kv1.3和hERG通道抑制.
主要成果:
- 确定了9种新的和16种已知的二类物种,其中包括雅特罗,拉提兰,英,阿比和阿提桑骨.
- 宏循环亚特罗和拉提兰显示出显著的Kv1.3阻断活性.
- 化合物8显示Kv1.3对hERG通道具有很高的选择性 (选择性指数>7.0).
结论:
- 来自Euphorbia fischeriana的宏环二类物质具有强大的Kv1.3抑制活性.
- 拉提兰二甲类的选择性Kv1.3抑制突出了它们的治疗潜力.
- 这些发现支持进一步调查diterpenoids作为治疗自身免疫性疾病的药物.
更多相关视频
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
10:07High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
Published on: January 27, 2013
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Drugs Affecting Neurotransmitter Release or Uptake
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Dose-Response Relationship: Potency and Efficacy
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
